• Sitemap
  • Contact Us

pISSN 2950-9114 eISSN 2950-9122
Article View

Report On Proficiency Testing

Lab Med Qual Assur 2021; 43(4): 167-175

Published online December 31, 2021


Copyright © Korean Association of External Quality Assessment Service.

Annual Report of the Korean Association of External Quality Assessment Service on Transfusion Medicine (2020)

Hee-Jeong Youk1 , Jin Seok Kim1 , John Jeongseok Yang1 , Hyungsuk Kim2 , and Dae-Hyun Ko1

1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine; 2Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea

Correspondence to:Dae-Hyun Ko
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel +82-2-3010-4504
E-mail daehyuni1118@amc.seoul.kr

Hyungsuk Kim
Department of Laboratory Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel +82-2-2072-3500
E-mail hyungsuk_kim@snuh.org

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


This report summarizes the 2020 survey results of the external quality assessment (EQA) scheme for the Transfusion Medicine Program (TMP) in Korea. Proficiency testing materials were prepared at Asan Medical Center for biannual distribution to the participating laboratories. The accuracy rates and number of participants for the 10 survey items were as follows: ABO typing, 99.6%–99.9% (n=890/897); RhD typing, 99.7%–100.0% (n=877/885); crossmatching, 94.0%–99.1% (n=771/780); ABO subgroup typing, 95.2%–98.4% (n=62/63); Rh CcEe antigen, 100% (n=56/58); weak D test, 92.8%–98.4% (n=250/252); antibody screening, 99.7%–100.0% (n=327/329); direct antiglobulin test (DAT) using a polyspecific reagent, 97.2%–99.7% (n=283/286); DAT using anti-immunoglobulin-G monospecific reagent, 88.7%–100.0% (n=71/71); DAT using anti-C3d monospecific reagent, 97.2%–100.0% (n=70/72); antibody identification, 68.9%–100% (n=135/135); and ABO antibody titration, 94.3%–100.0% (n=140/142). As compared to last year’s EQA report, there was an average increase of 5.1% in the number of participating laboratories across the 10 survey items, with the ABO subgroup typing and weak D test showing the highest increase of 8.6%. Although the overall results were excellent, only 68.9% of the participants precisely detected samples with anti-C and anti-e in the EQA conducted in the first half of 2020. The 2020 EQA scheme for TMP has contributed to the improvement and maintenance of the participating laboratories in the program.

Keywords: Transfusion medicine, Quality improvement, Laboratory proficiency testing

Supplementary File

Share this article on :

Stats or metrics